Sort   by:  
 Page size 
TranscriptomicsTranscriptomic characterization of the impact of 2'-fucosyllactose supplementation on intestinal adaptation following ileocecal resection.
Purpose: To identify the impact of 2'-FL supplementation on adaptive response following extensive intestinal resection. Methods: Transcriptomic profiles were obtained from mice undergoing ileocecal recection (8-10 week old male mice) and again at 8 weeks post-surgery. At the time of resection and...
ORGANISM(S): Mus musculus 
2016-04-01 | E-GEOD-72590 | biostudies-arrayexpress
MetabolomicsModulating the developing gut microbiota with 2’-fucosyllactose and pooled human milk oligosaccharides

Synthetic human milk oligosaccharide (HMO) structures are used to supplement infant formula despite limited understanding of their impact on the developing gut microbiota. Here, we assess the impact of 2-fucosyllactose (2’FL) and pooled (p)HMOs on the composition and activity of cultured microbia...

2024-09-03 | MTBLS9853 | MetaboLights
ProteomicsBifidobacterium infantis metabolizes 2´fucosyllactose-derived and free fucose through a common catabolic pathway resulting in 1,2-propanediol secretion
Human milk oligosaccharides (HMOs) are highly diverse complex carbohydrates secreted in human milk. HMOs are indigestible by the infant and instead are metabolized by bifidobacteria in the infant gut microbiome to produce molecules that promote infant health and development. 2´fucosyllactose (2´FL) ...
ORGANISM(S): Bifidobacterium longum subsp. infantis (strain ATCC 15697 / DSM 20088 / JCM 1222 / NCTC 11817 / S12) 
2021-03-17 | PXD021868 | Pride
Human milk oligosaccharides Bifidobacteria Microbiome Fucose Microbiota 2'fucosyllactose 
TranscriptomicsStrain-specific strategies of 2′-fucosyllactose, 3-fucosyllactose, and difucosyllactose assimilation by Bifidobacterium longum subsp. infantis Bi-26 and ATCC 15697
Human milk oligosaccharides (HMOs) function as prebiotics for beneficial bacteria in the developing gut, often dominated by Bifidobacterium spp. To understand the relationship between Bifidobacterium utilizing HMOs and how the metabolites that are produced could affect the host, we analyzed the meta...
ORGANISM(S): Bifidobacterium longum subsp. infantis 
2020-06-07 | GSE151933 | GEO
TranscriptomicsThe human milk oligosaccharide 2’-fucosyllactose alleviates liver steatosis and associated gut permeability, ER stress and insulin resistance by reducing hepatic diacylglycerols in obese Ldlr-/-.Leiden mice
Abstract: - Non-alcoholic fatty liver disease (NAFLD) is a complex multifactorial disorder that is associated with gut dysbiosis, enhanced gut permeability, adiposity and insulin resistance. Prebiotics such as human milk oligosaccharide 2’-fucosyllactose are thought to primarily improve gut health a...
ORGANISM(S): Mus musculus 
2022-05-24 | GSE195862 | GEO
GenomicsStrain-Specific Strategies of Human Milk Oligosaccharide 2′-Fucosyllactose, 3-Fucosyllactose, and Difucosyllactose Assimilation by Bifidobacterium longum subsp. infantis Strains Bi-26 and ATCC 15697
Strain-Specific Strategies of Human Milk Oligosaccharide 2′-Fucosyllactose, 3-Fucosyllactose, and Difucosyllactose Assimilation by Bifidobacterium longum subsp. infantis Strains Bi-26 and ATCC 15697
PRJNA637762 | ENA
GenomicsThe human milk oligosaccharide 2’-fucosyllactose alleviates liver steatosis and associated gut permeability, ER stress and insulin resistance by reducing hepatic diacylglycerols in obese Ldlr-/-.Leiden mice
The human milk oligosaccharide 2’-fucosyllactose alleviates liver steatosis and associated gut permeability, ER stress and insulin resistance by reducing hepatic diacylglycerols in obese Ldlr-/-.Leiden mice
PRJNA802366 | ENA
UnknownOligofructose alone and in combination with 2'fucosyllactose induces physiologically relevant changes in γ-aminobutyric acid and organic acid production compared to sole 2'fucosyllactose supplementation: an in vitro study.
Not available
S-EPMC10481994 | biostudies-literature
ProteomicsThe human milk oligosaccharide 2’-fucosyllactose protects against high-fat diet induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and fecal proteome profiles in mice
The aim of this study was to decipher the mechanisms by which the major human milk oligosaccharide (HMO), 2’-fucosyllactose (2’FL), can affect body weight and fat mass gain upon high-fat diet (HFD) feeding in mice. In particular, we wanted to elucidate whether 2’FL metabolic effects are linked with ...
ORGANISM(S): Mus musculus (Mouse) Bacteria 
2025-05-06 | PXD049406 | Pride
Human milk oligosaccharides Obesity Gut barrier. Gut microbiota Mucus Fecal proteome Diabetes 
UnknownMulti-level metabolic engineering of Escherichia coli for high-titer biosynthesis of 2'-fucosyllactose and 3-fucosyllactose.
Not available
S-EPMC9733645 | biostudies-literature
Sort   by:  
 Page size